FR2786104B1 - Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques - Google Patents

Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques

Info

Publication number
FR2786104B1
FR2786104B1 FR9814858A FR9814858A FR2786104B1 FR 2786104 B1 FR2786104 B1 FR 2786104B1 FR 9814858 A FR9814858 A FR 9814858A FR 9814858 A FR9814858 A FR 9814858A FR 2786104 B1 FR2786104 B1 FR 2786104B1
Authority
FR
France
Prior art keywords
inhibitors
activation
pharmaceutical uses
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9814858A
Other languages
English (en)
Other versions
FR2786104A1 (fr
Inventor
Francois Hirsch
Astrid Haeffner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9814858A priority Critical patent/FR2786104B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US09/856,796 priority patent/US6914046B1/en
Priority to EP99958229A priority patent/EP1131088A2/fr
Priority to JP2000583472A priority patent/JP2002537224A/ja
Priority to PCT/FR1999/002897 priority patent/WO2000030587A2/fr
Priority to CA002351733A priority patent/CA2351733A1/fr
Priority to AU15643/00A priority patent/AU1564300A/en
Publication of FR2786104A1 publication Critical patent/FR2786104A1/fr
Application granted granted Critical
Publication of FR2786104B1 publication Critical patent/FR2786104B1/fr
Priority to US11/144,889 priority patent/US20050272654A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
FR9814858A 1998-11-25 1998-11-25 Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques Expired - Fee Related FR2786104B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9814858A FR2786104B1 (fr) 1998-11-25 1998-11-25 Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
EP99958229A EP1131088A2 (fr) 1998-11-25 1999-11-24 INHIBITEURS DE L'ACTIVATION DE NF-$g(k)B, ET LEURS UTILISATIONS PHARMACEUTIQUES
JP2000583472A JP2002537224A (ja) 1998-11-25 1999-11-24 ＮＦ−κＢ活性化阻害剤及びそれらの医薬としての使用
PCT/FR1999/002897 WO2000030587A2 (fr) 1998-11-25 1999-11-24 INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES
US09/856,796 US6914046B1 (en) 1998-11-25 1999-11-24 NF-κB activation inhibitors, and their pharmaceutical uses
CA002351733A CA2351733A1 (fr) 1998-11-25 1999-11-24 Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
AU15643/00A AU1564300A (en) 1998-11-25 1999-11-24 NF-kB activation inhibitors, and their pharmaceutical uses
US11/144,889 US20050272654A1 (en) 1998-11-25 2005-06-06 NF-kappaB activation inhibitors, and their pharmaceutical uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9814858A FR2786104B1 (fr) 1998-11-25 1998-11-25 Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques

Publications (2)

Publication Number Publication Date
FR2786104A1 FR2786104A1 (fr) 2000-05-26
FR2786104B1 true FR2786104B1 (fr) 2002-12-27

Family

ID=9533184

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9814858A Expired - Fee Related FR2786104B1 (fr) 1998-11-25 1998-11-25 Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques

Country Status (7)

Country Link
US (2) US6914046B1 (fr)
EP (1) EP1131088A2 (fr)
JP (1) JP2002537224A (fr)
AU (1) AU1564300A (fr)
CA (1) CA2351733A1 (fr)
FR (1) FR2786104B1 (fr)
WO (1) WO2000030587A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496880A4 (fr) * 2002-04-24 2007-12-12 Res Dev Foundation EFFETS SYNERGETIQUES DES INHIBITEURS DU FACTEUR NF-kB DE TRANSCRIPTION NUCLEAIRE ET D'AGENTS ANTI-CANCEREUX
US20060183794A1 (en) * 2002-06-26 2006-08-17 Kazuo Umezawa Drug composition containing nf-kb inhibitor
GB0228441D0 (en) * 2002-12-05 2003-01-08 Ares Trading Sa Splice variant
CA2515658A1 (fr) * 2003-02-14 2004-08-26 Keio University Preparation curative
EP2972360B1 (fr) * 2013-03-15 2018-03-07 Translate Bio, Inc. Stimulation synergique de l'administration d'acides nucléiques par le biais de formulations mélangées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer

Also Published As

Publication number Publication date
JP2002537224A (ja) 2002-11-05
EP1131088A2 (fr) 2001-09-12
US20050272654A1 (en) 2005-12-08
US6914046B1 (en) 2005-07-05
WO2000030587A2 (fr) 2000-06-02
FR2786104A1 (fr) 2000-05-26
WO2000030587A3 (fr) 2000-09-14
CA2351733A1 (fr) 2000-06-02
AU1564300A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
DZ2797A1 (fr) Compositions pharmaceutiques enrobées entériques et leurs mésthodes de fabrication.
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
ATE263558T1 (de) Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
PT869126E (pt) Derivados de ditiolano, sua preparacao e seus efeitos terapeuticos
BR0000276B1 (pt) conjunto de condicionamento e de aplicação de um produto.
MA26550A1 (fr) Composes heteromatiques et leurs usages en medecine
ATE246490T1 (de) Pharmazeutische zusammensetzung von topiramate
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
BR0000620B1 (pt) conjunto de condicionamento e de aplicaÇço de um produto.
BR9507999A (pt) Conjugado biologicamente ativo composto substancialmente purificado polimero solúvel em água e composição farmacêutica
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
FR2785543B1 (fr) Exosomes modifies et utilisations
EE04500B1 (et) Trombiini inhibiitorid, nende saamine ja kasutamine
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
MA26491A1 (fr) Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant .
BR0014465B1 (pt) 1,1'-bifenil-2-carbonamidas 2'-substituÍdas, preparado farmacÊutico e aplicaÇÕes dos referidos compostos.
ATE299135T1 (de) Hydroxypyridinone
FR2751966B1 (fr) Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2772599B1 (fr) Composition cosmetique et ses utilisations
FR2731706B1 (fr) Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
PT1140835E (pt) Derivados da 3,3-biarilpiperidina e 2,2-biarilmorfolina
FR2769311B1 (fr) Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
DE59610836D1 (de) Mittel gegen parasitäre protozoen
FR2786104B1 (fr) Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080930